[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceutical

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. T

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Michael Hayden purchased 15,00

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Wall Street analysts changed outlook on top names: Barclays cut META price target, Needham boosted Q

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial produ

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Cons

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that F

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: I

Entropy Technologies LP purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during t

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lower

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

U.S. stock futures mixed, Dow down 0.1%. Levi Strauss shares down 6.1%, Noah Holdings down 14%, Ioni

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, p

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear